ABCB1 and coronary artery disorder: The EPIC-CAD trial compared edoxaban monotherapy (60 mg o.d.; 30 mg o.d. with CrCl 15–50 mL/min, body weight ≤60 kg, and use of certain P-glycoprotein inhibitors) with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in 554 patients with AF (mean CHA2DS2-VASc score 4.3) and stable CAD.